The following table summarizes the components of the Company’s other intangible assets (in thousands):


	June 30, 2025						December 31, 2024
	Cost		Accumulated Amortization		Net Carrying Value		Cost		Accumulated Amortization		Net Carrying Value
Indefinite-lived intangible assets
In-process research and development (IPR&D)	$	50,000	$	-	$	50,000	$	50,000	$	-	$	50,000
Total	$	50,000	$	-	$	50,000	$	50,000	$	-	$	50,000

The Company’s IPR&D assets represent the estimated fair value of its pipeline of acquired radiotherapy product candidates. The Company tests its indefinite-lived intangible assets for impairment during the fourth quarter of each year, or more frequently should circumstances change or events occur that would more likely than not reduce the fair value of its assets. No testing was deemed necessary during the three and six months ended June 30, 2025. For additional information related to the Company’s IPR&D assets, see Notes 2, 4 and 10 in the Company’s 2024 Form 10-K.